Bisphosphonates are a class of drugs that slow bone loss by shutting down the cells responsible for breaking down bone tissue. They are the most widely prescribed medications for osteoporosis and have been in clinical use for decades. Your body constantly breaks down old bone and builds new bone, and bisphosphonates work by tipping that balance toward preservation, keeping bones denser and less likely to fracture.
How Bisphosphonates Work
Bone is living tissue in a constant cycle of renewal. Specialized cells called osteoclasts dissolve old bone, while other cells called osteoblasts lay down new bone in its place. In osteoporosis, osteoclasts outpace osteoblasts, and bone gradually thins. Bisphosphonates target the osteoclasts directly.
Once you take a bisphosphonate, the drug travels through your bloodstream and binds tightly to bone mineral surfaces, particularly in areas where bone is actively being broken down. When an osteoclast lands on that surface and begins dissolving bone, it absorbs the drug. What happens next depends on the type of bisphosphonate.
The newer, more potent versions (called nitrogen-containing bisphosphonates) block an enzyme the osteoclast needs to maintain its structure and stay attached to bone. Without that enzyme, the cell loses its grip, its internal scaffolding collapses, and it self-destructs. Older bisphosphonates take a different route: they get built into a faulty version of the cell’s main energy molecule, poisoning the osteoclast’s metabolism from the inside. Either way, the result is fewer active bone-destroying cells and slower bone loss.
What Bisphosphonates Treat
The FDA has approved bisphosphonates for a surprisingly broad range of bone-related conditions:
- Osteoporosis in postmenopausal women and in men, including both treatment and prevention
- Steroid-induced osteoporosis, which develops in people taking corticosteroids long-term
- Paget’s disease of bone, a condition where bone remodeling goes haywire, producing enlarged, misshapen bones
- Cancer-related bone problems, including dangerously high blood calcium levels caused by tumors, cancer that has spread to bone, and multiple myeloma
Osteoporosis is by far the most common reason people are prescribed a bisphosphonate. For cancer patients, these drugs serve a different purpose: slowing down the bone destruction that tumors cause and reducing skeletal complications like fractures and bone pain.
Common Bisphosphonate Medications
Bisphosphonates come in both pill and IV (intravenous) forms. The oral options currently prescribed in the U.S. are alendronate (Fosamax), risedronate (Actonel), and ibandronate (Boniva). Ibandronate is also available as an IV infusion. The IV-only options are pamidronate (Aredia) and zoledronic acid, sold as Reclast for osteoporosis and Zometa for cancer-related bone conditions.
Oral bisphosphonates are typically taken daily or weekly. IV versions are given less frequently, sometimes as rarely as once a year for zoledronic acid in osteoporosis. The choice between oral and IV often comes down to whether a patient can tolerate the pill’s strict dosing requirements or has a condition severe enough to warrant infusion.
How to Take Oral Bisphosphonates
Oral bisphosphonates are absorbed very poorly by the gut, so the dosing instructions are unusually strict. You need to take the pill first thing in the morning on a completely empty stomach, with a full glass of plain water (not coffee, juice, or mineral water). Then you must wait at least 30 minutes before eating, drinking anything else, or taking any other medications, including calcium supplements and antacids.
During that 30-minute window, you should stay upright. Do not lie back down. Sitting, standing, and walking are all fine. The reason is that bisphosphonates can irritate or even ulcerate the esophagus if the pill lingers there. Staying upright and using plenty of water helps the medication move quickly into the stomach. Taking it at bedtime or before you’re ready to get up for the day is not recommended.
How Long They Stay in Your Body
One of the most distinctive features of bisphosphonates is their persistence. Once embedded in bone, they stay there for years. Alendronate has an estimated half-life in bone of about 10 years. In one long-term study, pamidronate was still detectable in patients’ urine up to 8 years after they had stopped treatment, with some individuals tracked for observation periods as long as 19 years total.
This happens because the drug gets locked into the bone mineral matrix. It sits there quietly until that patch of bone eventually gets remodeled, at which point the drug is slowly released. This long residency is actually part of what makes bisphosphonates effective: their bone-protecting effects can linger well beyond the last dose, which is why doctors sometimes recommend planned treatment breaks.
Drug Holidays
Because bisphosphonates accumulate in bone and continue working after you stop taking them, many doctors will recommend a “drug holiday” after several years of treatment. A 2024 position statement from the American Society for Bone and Mineral Research notes that once bone density targets have been reached, a pause in bisphosphonate therapy may be appropriate. During a holiday, the drug stored in your bones continues to release slowly, maintaining some degree of protection.
The rationale for drug holidays is not just convenience. Extended bisphosphonate use is linked to two rare but serious complications: atypical femoral fractures and osteonecrosis of the jaw. Taking a break may help reduce the risk of these events while the residual drug in bone continues to work. The optimal length of both treatment and holidays is still being refined, and the decision typically depends on your individual fracture risk and bone density trends.
Side Effects
The most common side effects of oral bisphosphonates involve the upper digestive tract: heartburn, nausea, and irritation of the esophagus. Following the dosing instructions carefully, particularly the upright posture and water requirements, significantly reduces this risk. IV bisphosphonates can cause a brief flu-like reaction (fever, muscle aches, fatigue) after the first infusion, which typically resolves within a day or two and is less common with subsequent doses.
Less common side effects include impaired kidney function and low blood calcium. All bisphosphonates carry a warning or contraindication for people with severe kidney impairment, generally defined as a creatinine clearance below 30 to 35 mL/min.
Osteonecrosis of the Jaw
This is the side effect that generates the most concern, though it remains rare, particularly at the doses used for osteoporosis. Osteonecrosis of the jaw involves a section of jawbone that becomes exposed and fails to heal within eight weeks. It is more commonly seen in cancer patients receiving high-dose IV bisphosphonates than in osteoporosis patients on oral pills. Risk factors include dental surgery, poorly fitting dentures, and other trauma to the jaw. If you’re starting a bisphosphonate, your doctor may recommend getting any needed dental work done beforehand.
Atypical Femoral Fractures
With long-term use, there is a small risk of unusual fractures in the thighbone. These fractures occur in the shaft of the femur rather than at the hip joint, often with minimal trauma, and sometimes preceded by a dull ache in the thigh. They are thought to result from bone becoming overly suppressed in its remodeling cycle, making it brittle in a different way than osteoporotic bone. This risk is one of the main reasons drug holidays are recommended after several years of continuous therapy.
Who Should Not Take Bisphosphonates
People with severe kidney disease (creatinine clearance below 30 to 35 mL/min, depending on the specific drug) should not use bisphosphonates. Those with active esophageal problems or an inability to stay upright for 30 minutes are not good candidates for oral forms, though IV options may still be appropriate. Low blood calcium levels need to be corrected before starting treatment, since bisphosphonates can lower calcium further. A history of allergic reactions to any bisphosphonate rules out the entire class.